| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| J M Marjama-Lyons, W C Kolle. Parkinson's disease. Update in diagnosis and symptom management. Geriatrics. vol 56. issue 8. 2001-09-06. PMID:11505857. |
recent studies have shown a lower incidence of dyskinesia in patients who began therapy with a dopamine agonist, although levodopa may be better tolerated by patients age 70 or older. |
2001-09-06 |
2023-08-12 |
Not clear |
| W Pirker, J Tedroff, H Pontén, L Gunne, P E Andrén, Y L Hur. Coadministration of (-)-OSU6162 with l-DOPA normalizes preproenkephalin mRNA expression in the sensorimotor striatum of primates with unilateral 6-OHDA lesions. Experimental neurology. vol 169. issue 1. 2001-06-07. PMID:11312565. |
the substituted phenylpiperidine (-)-osu6162 is a novel modulator of the dopaminergic systems with low affinity for dopamine d(2) receptors and potent normalizing effects on l-dopa-induced dyskinesias. |
2001-06-07 |
2023-08-12 |
monkey |
| A Hadj Tahar, A Ekesbo, L Grégoire, E Bangassoro, K A Svensson, J Tedroff, P J Bédar. Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys. European journal of pharmacology. vol 412. issue 3. 2001-05-10. PMID:11166288. |
effects of acute and repeated treatment with a novel dopamine d2 receptor ligand on l-dopa-induced dyskinesias in mptp monkeys. |
2001-05-10 |
2023-08-12 |
monkey |
| R Løvlie, R Thara, R Padmavathi, V M Steen, R G McCreadi. Ser9Gly dopamine D3 receptor polymorphism and spontaneous dyskinesia in never-medicated schizophrenic patients. Molecular psychiatry. vol 6. issue 1. 2001-05-10. PMID:11244476. |
ser9gly dopamine d3 receptor polymorphism and spontaneous dyskinesia in never-medicated schizophrenic patients. |
2001-05-10 |
2023-08-12 |
Not clear |
| T Boraud, E Bezard, B Bioulac, C E Gros. Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey. Brain : a journal of neurology. vol 124. issue Pt 3. 2001-04-05. PMID:11222455. |
dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the mptp-treated monkey. |
2001-04-05 |
2023-08-12 |
monkey |
| T Boraud, E Bezard, B Bioulac, C E Gros. Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey. Brain : a journal of neurology. vol 124. issue Pt 3. 2001-04-05. PMID:11222455. |
in this study, electrophysiological single-unit recordings of the neuronal activity of the globus pallidus internalis (gpi), the main basal ganglia output structure, and the globus pallidus externalis (gpe) were recorded continuously in both normal and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treated subhuman primates before and after the administration of three dopamine agonists--apomorphine (a dopaminergic mixed agonist), skf-38393 (a d1 partial agonist) and piribedil (a d2/d3 agonist)--at doses known to induce dyskinesias in the parkinsonian monkey. |
2001-04-05 |
2023-08-12 |
monkey |
| T Boraud, E Bezard, B Bioulac, C E Gros. Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey. Brain : a journal of neurology. vol 124. issue Pt 3. 2001-04-05. PMID:11222455. |
however, the similarity between the induced decrease in firing frequency in normal and parkinsonian animals underlines the need for dopamine depletion in the induction of dyskinesias. |
2001-04-05 |
2023-08-12 |
monkey |
| O Rascol, J G Nutt, O Blin, C G Goetz, J M Trugman, C Soubrouillard, J H Carter, L J Currie, N Fabre, C Thalamas, W W Giardina, S Wrigh. Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Archives of neurology. vol 58. issue 2. 2001-03-29. PMID:11176963. |
induction by dopamine d1 receptor agonist abt-431 of dyskinesia similar to levodopa in patients with parkinson disease. |
2001-03-29 |
2023-08-12 |
Not clear |
| O Rascol, J G Nutt, O Blin, C G Goetz, J M Trugman, C Soubrouillard, J H Carter, L J Currie, N Fabre, C Thalamas, W W Giardina, S Wrigh. Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Archives of neurology. vol 58. issue 2. 2001-03-29. PMID:11176963. |
the relative contribution of dopamine d(1) and d(2) receptor function to the pathophysiology of levodopa-induced dyskinesias remains a matter of controversy. |
2001-03-29 |
2023-08-12 |
Not clear |
| R Inzelberg, R L Carasso, E Schechtman, P Nisipean. A comparison of dopamine agonists and catechol-O-methyltransferase inhibitors in Parkinson's disease. Clinical neuropharmacology. vol 23. issue 5. 2001-03-08. PMID:11154093. |
all drugs caused more dyskinesias than placebo (p < 0.0001), with overlapping confidence intervals, except for tol 600 mg, which caused more dyskinesias than dopamine agonists and ent. |
2001-03-08 |
2023-08-12 |
Not clear |
| J M Van Kampen, A J Stoess. Dopamine D(1A) receptor function in a rodent model of tardive dyskinesia. Neuroscience. vol 101. issue 3. 2001-03-01. PMID:11113312. |
the emergence of such dyskinesias may reflect a shift in the balance of dopamine d(1) and d(2) receptor-mediated activity, with a relative increase in activity in the d(1) receptor-regulated direct striatonigral pathway. |
2001-03-01 |
2023-08-12 |
human |
| H Reichman. Long-term treatment with dopamine agonists in idiopathic Parkinson's disease. Journal of neurology. vol 247 Suppl 4. 2001-02-15. PMID:11199810. |
there are open studies comparing bromocriptine, lisuride, pergolide with levodopa which demonstrate that the use of dopamine agonists in monotherapy or combination with levodopa decreases the percentage of patients who develop dyskinesias compared to levodopa only. |
2001-02-15 |
2023-08-12 |
Not clear |
| F Calon, A Hadj Tahar, P J Blanchet, M Morissette, R Grondin, M Goulet, J P Doucet, G S Robertson, E Nestler, T Di Paolo, P J Bédar. Dopamine-receptor stimulation: biobehavioral and biochemical consequences. Trends in neurosciences. vol 23. issue 10 Suppl. 2001-02-08. PMID:11052226. |
it is proposed that l-dopa-induced dyskinesias represent a form of pathological learning caused by chronic pulsatile (nonphysiological) stimulation of dopamine receptors, which activates a cascade of molecular and biochemical events. |
2001-02-08 |
2023-08-12 |
monkey |
| J J Ferreira, O Rasco. Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease. Current opinion in neurology. vol 13. issue 4. 2000-12-22. PMID:10970061. |
however, the conclusive demonstration of the benefits associated with early prescription of a dopamine agonist, the antidyskinetic properties of 'old' antiparkinsonian compounds such as amantadine, and the striking results of functional stereotatic neurosurgery are extremely important advances for the treatment of levodopa-induced dyskinesias. |
2000-12-22 |
2023-08-12 |
Not clear |
| L M Shulma. How to succeed in using dopamine agonists in Parkinson's disease. European journal of neurology. vol 7 Suppl 1. 2000-11-30. PMID:11054153. |
in the patient with advanced disease, all four dopamine agonists significantly augment the response to levodopa, which reduces the problems of motor fluctuations and drug related dyskinesia. |
2000-11-30 |
2023-08-12 |
Not clear |
| L He, D A Di Monte, J W Langston, M Qui. Autoradiographic analysis of N-methyl-D-aspartate receptor binding in monkey brain: effects of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine and levodopa treatment. Neuroscience. vol 99. issue 4. 2000-11-07. PMID:10974432. |
the data indicate that levodopa exerts a modulatory effect on the striatal glutamatergic system and suggest that a down-regulation of n-methyl-d-aspartate receptors by levodopa, combined with a deficiency in nigrostriatal dopamine function, may play a role in the development of levodopa induced dyskinesias. |
2000-11-07 |
2023-08-12 |
monkey |
| P Izurieta-Sánchez, S Sarre, G Ebinger, Y Michott. Muscarinic antagonists in substantia nigra influence the decarboxylation of L-dopa in striatum. European journal of pharmacology. vol 399. issue 2-3. 2000-09-22. PMID:10884514. |
we postulate that drugs that enhance dopamine release, after l-dopa administration, in a less extreme way than l-dopa administered on its own could prevent further neurodegeneration and dyskinesias thought to result from extremely high extracellular dopamine levels following l-dopa treatment. |
2000-09-22 |
2023-08-12 |
rat |
| A Hadj Tahar, N Bélanger, E Bangassoro, L Grégoire, P J Bédar. Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys. European journal of pharmacology. vol 399. issue 2-3. 2000-09-22. PMID:10884518. |
the present results suggest that novel selective dopamine d(4) receptor antagonists may represent a useful tool to reduce l-dopa-induced dyskinesias. |
2000-09-22 |
2023-08-12 |
monkey |
| P Jenne. Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. Journal of neurology. vol 247 Suppl 2. 2000-09-14. PMID:10991665. |
the development of dyskinesia is dependent on the extent of nigral denervation but can be induced through both d-1 and d-2 dopamine receptors. |
2000-09-14 |
2023-08-12 |
Not clear |
| P Jenne. Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. Journal of neurology. vol 247 Suppl 2. 2000-09-14. PMID:10991665. |
short-acting dopamine agonists producing pulsatile receptor stimulation are more likely to induce dyskinesia than long-acting drugs that produce continuous receptor stimulation. |
2000-09-14 |
2023-08-12 |
Not clear |